Prevalence And Predictive Factors of Advanced Cholangiocarcinoma Patient in Chemotherapy Treatment
Keywords:
cholangiocarcinoma, chemotherapy, predictive factor, response of treatmentAbstract
Cholangiocarcinoma is one of the health problem in Thailand, commonly found in North-Eastern and Northern province, usually present with unresectable disease which need systemic chemotherapy for treatment. The poor prognosis of this cancer most present with late presentation with unresectable disease, the limited systemic chemotherapy regimen. The purpose of this study was to find incidence rate of disease control group in patients who received treatment in Udonthani hospital during year 2017-2021. In this retrospective cohort study, sampling were advanced cholangiocarcinoma patients who received chemotherapy treatment at Udonthani hospital during year 2017-2021. Data collected from medical records. Statistical analysis used descriptive and logistic regression.
Results show 95 patients had disease control 31 patients(32.6%) and 64 patients in no response group(67.4%). Predictive factors of disease control response evaluate by univariate logistic regression found ECOG performance status ( odd ratio 4.1 for ECOG 0 vs ECOG 1-3), stage of disease (odd ratio 6.0 for locally advanced vs metastatic disease) and site of disease ( odd ratio 5.96 compared extrahepatic vs intrahepatic); after evaluate with multivariable logistic regression found 2 factors; stage of disease (adjusted odd ratio 6.17 for locally advanced vs metastasis) and site of disease (adjusted odd ratio 6.48 for extrahepatic vs intrahepatic) were predictive factors for response to chemotherapy.
References
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13:261-80
Ustundag Y, Bayraktar Y. Cholangiocarcinoma, a compact review of the literature. World Journal of Gastroenterology: WJG 2008;14:6458-66
National Comprehensive Cancer Network. Hepatobiliary Cancer (Version 3.2022). http://www.nccn.org/professionals/
physician.gls/pdf/hepatobiliary.pdf
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic Cholangioca rcinoma
: An overview of the current and future
therapeutic landscape for clinicians. CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19. PMID: 36260350.
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690-701.
Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, et al. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014 Dec;5(6):408-13. doi: 10.3978/j.issn.
-6891.2014.072.
Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81.
Pavicevic S, Reichelt S, Uluk D, Lurje I, Engelmann C, Modest DP, et al. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers (Basel). 2022;14(4):1026. Published 2022 Feb 17. doi:10.3390/cancers14041026
Neelakan, P. Correlation of tumor
marker CA 19-9 in cholangiocarcinoma patient
after receiving chemotherapy, 2021. [Unpublished medicine resident master’s thesis]; Mahidol university
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. PMID: 7165009.
Taïeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002 Aug;13(8):1192-6. doi: 10.1093/annonc/mdf201. PMID: 12181241.
Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, et al. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol 54, 281–290 (2019).
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
การละเมิดลิขสิทธิ์ถือเป็นความรับผิดชอบของผู้ส่งบทความโดยตรง
ผลงานที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของผู้นิพนธ์ ขอสงวนสิทธิ์มิให้นำเนื้อหา ทัศนะ หรือข้อคิดเห็นใด ๆ ของบทความในวารสารไปเผยแพร่ทางการค้าก่อนได้รับอนุญาตจากกองบรรณาธิการ อย่างเป็นลายลักษณ์อักษร